Triumeq

Indications for Use

Triumeq is a complete treatment regimen used to manage HIV-1 infection. It combines three different antiretroviral medicines—abacavir, dolutegravir, and lamivudine—into a single pill. These components work together to help control the virus in the body.

The primary purposes of this treatment are to:

• Reduce viral load: Decrease the amount of HIV in the blood to very low levels.
• Support the immune system: Increase the number of CD4 (T) cells, which are white blood cells that help the body fight off infections.

Patient Population

Triumeq is prescribed for:

• Adults with HIV-1 infection.
• Children weighing at least 10 kilograms (approximately 22 pounds).

Before starting this medication, healthcare providers perform a blood test to check for a genetic marker called HLA-B*5701. This test is required because individuals with this gene variation are at a significantly higher risk of having a serious allergic reaction to the abacavir component of the medication.

Important Considerations

It is important to understand that Triumeq is not a cure for HIV or AIDS. While it helps manage the virus and supports the immune system, patients may still develop opportunistic infections or other complications associated with HIV infection. The medication must be taken exactly as prescribed to maintain its effectiveness in controlling the virus.

Mechanism of Action

Triumeq contains three active ingredients: abacavir, dolutegravir, and lamivudine. These medications belong to a class of drugs known as antiretrovirals, which work by interfering with the enzymes HIV needs to replicate within the body.

The medication works through two primary mechanisms:

• Blocking Integration: Dolutegravir is an integrase strand transfer inhibitor (INSTI). It prevents the HIV integrase enzyme from inserting viral DNA into the host cell's DNA, which stops the virus from taking over the cell to make copies of itself.
• Blocking Replication: Abacavir and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs). They block the reverse transcriptase enzyme, which the virus uses to convert its RNA into DNA. Without this conversion, the virus cannot reproduce.

By combining these actions, Triumeq helps decrease the viral load (the amount of HIV in the blood) and increase the number of CD4 cells, which are white blood cells that help the body fight infection. While Triumeq helps manage HIV and reduces the risk of transmission, it is not a cure for HIV or AIDS.

Common Side Effects

Some people taking Triumeq may experience mild side effects. These often improve as the body adjusts to the medication. Common side effects include:

• Headache
• Difficulty falling asleep or staying asleep
• Tiredness or lack of energy

Serious Side Effects

Contact a healthcare provider immediately if you experience any of the following serious side effects:

Allergic Reactions

Triumeq contains abacavir, which can cause a serious and sometimes fatal allergic reaction. Seek emergency medical help if you develop a rash or symptoms from two or more of the following groups:

• Fever
• Nausea, vomiting, diarrhea, or stomach pain
• General ill feeling, extreme tiredness, or body aches
• Shortness of breath, cough, or sore throat

Liver Problems

Signs of liver damage may include:

• Yellowing of the skin or the whites of the eyes (jaundice)
• Dark-colored urine or light-colored stools
• Pain on the right side of the stomach area
• Loss of appetite

Lactic Acidosis

This is a rare but serious condition where acid builds up in the blood. Symptoms may include:

• Unusual muscle pain or weakness
• Feeling cold, especially in the arms and legs
• Dizziness or lightheadedness
• Fast or irregular heartbeat

Immune System Changes

As the immune system gets stronger, it may react to hidden infections already in the body. This is known as immune reconstitution syndrome and can cause new symptoms to appear shortly after starting treatment.

Boxed Warnings

Hypersensitivity Reactions

Serious and sometimes fatal hypersensitivity reactions can occur with abacavir, a component of Triumeq. Patients must be screened for the HLA-B*5701 allele before starting or restarting treatment. Those who test positive for this genetic marker should not take Triumeq. Symptoms often include fever, rash, nausea, vomiting, diarrhea, abdominal pain, fatigue, or respiratory issues like sore throat and cough. If a hypersensitivity reaction is suspected, the medication must be stopped immediately and never restarted.

Exacerbation of Hepatitis B

Patients with both HIV-1 and Hepatitis B virus (HBV) may experience severe, acute worsening of their hepatitis infection if they stop taking Triumeq. This is due to the lamivudine component. Liver function should be closely monitored for several months after discontinuing the drug in these patients.

Other Serious Precautions

Hepatotoxicity

Liver injury has been reported in patients receiving dolutegravir-containing products. Patients with underlying Hepatitis B or C may be at higher risk for elevated liver enzymes. Monitoring for liver toxicity is recommended for all patients during treatment.

Lactic Acidosis and Severe Hepatomegaly

The use of nucleoside analogues like abacavir and lamivudine has been associated with lactic acidosis (a buildup of acid in the blood) and severe liver enlargement with fatty deposits. These conditions can be fatal and may occur even without significantly abnormal liver enzyme tests.

Immune Reconstitution Syndrome

As the immune system strengthens during treatment, it may develop an inflammatory response to previous or hidden infections, such as tuberculosis or pneumonia. Autoimmune disorders may also occur many months after starting treatment.

Drug Interactions

Triumeq should not be taken with certain medications, such as dofetilide, due to the risk of life-threatening side effects. It is important to review all current medications with a healthcare provider to avoid dangerous interactions.

Pregnancy

The use of Triumeq during pregnancy requires careful consideration. One of its components, dolutegravir, has been linked to a small increased risk of neural tube defects (serious problems with the brain or spine) when taken at the time of conception or during early pregnancy. Healthcare providers often recommend a pregnancy test before starting Triumeq in people who can become pregnant.

If you are pregnant or planning to conceive, it is important to discuss the risks and benefits of continuing or starting Triumeq with your healthcare provider. They may suggest using effective contraception while taking this medication or may monitor the pregnancy more closely. An Antiretroviral Pregnancy Registry exists to track outcomes for children exposed to these medications in the womb.

Breastfeeding

In the United States and other regions where safe alternative feeding options are available, healthcare providers recommend that individuals with HIV do not breastfeed. This precaution is taken to prevent the transmission of HIV to the infant through breast milk. Furthermore, the active ingredients in Triumeq—abacavir, dolutegravir, and lamivudine—are known to pass into breast milk, and their potential effects on a nursing baby are not well understood.

Available Forms

Triumeq is supplied in the following forms for oral use:

• Film-coated tablets: These tablets are intended to be swallowed whole.
• Dispersible tablets: These tablets are designed to be dissolved in drinking water to create a suspension before being swallowed.

FDA Approval and Indications

Triumeq was approved by the U.S. Food and Drug Administration (FDA) as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. It is indicated for use in adults and pediatric patients weighing at least 25 kg. A specific formulation, Triumeq PD, is available for pediatric patients weighing at least 10 kg to less than 25 kg.

Boxed Warnings

The FDA requires a boxed warning for Triumeq due to several serious safety risks:

• Hypersensitivity Reactions: Serious and sometimes fatal allergic reactions can occur with the abacavir component. Patients must be screened for the HLA-B*5701 allele before starting treatment, as those with this genetic marker are at a higher risk.
• Hepatitis B Exacerbation: Patients with both HIV-1 and hepatitis B virus (HBV) may experience severe worsening of their hepatitis B if they stop taking Triumeq. Liver function should be closely monitored in these patients.
• Lactic Acidosis and Liver Problems: There is a risk of lactic acidosis (buildup of acid in the blood) and severe liver enlargement with fatty liver (hepatomegaly with steatosis), which can be life-threatening.

Regulatory Requirements

Due to the risk of hypersensitivity reactions, the FDA requires that patients receive a Warning Card to carry with them, which describes the symptoms of an allergic reaction. A Medication Guide must also be provided to every patient when the prescription is filled or refilled.

Insurance Coverage

Triumeq is generally covered by most private insurance plans, Medicare Part D, and Medicaid. However, the amount you pay out-of-pocket depends on your plan's specific benefits, such as deductibles and co-pays. Some plans may require prior authorization from a healthcare provider before they will cover the medication.

Generic Options

Generic versions of the abacavir, dolutegravir, and lamivudine combination are available. Generic drugs are usually more affordable than brand-name medications while providing the same therapeutic benefits. Availability may vary by pharmacy and insurance formulary.

Financial Assistance Programs

If you are concerned about the cost of Triumeq, there are several options that may help reduce the price:

• Co-pay Cards: The manufacturer may offer savings cards for patients with commercial insurance to help lower monthly out-of-pocket costs.
• Patient Assistance: Programs are often available for individuals who are uninsured or underinsured and meet certain income criteria. These programs may provide the medication at little or no cost.

You can speak with your healthcare provider or pharmacist to learn more about these programs and how to apply for financial support.